Osaka University

Terumo Kabushiki Kaisha

Other

Ono Pharmaceutical Co., Ltd.

Dai Nippon Printing Co., Ltd.

Sumitomo Bakelite Company Limited

Nipro Corporation

Nof Corporation

Asahi Intecc Co., Ltd.

Otsuka Pharmaceutical Factory, Inc.

Rohto Pharmaceutical Co., Ltd.

Saraya Co., Ltd.

Cellseed, Inc.

Stemrim Inc.

Foundation for Biomedical Research and Innovation

Yoshiki Sawa

Shigeru Miyagawa

Atsuhiro Saito

Satsuki Fukushima

Mitsuru Akashi

Katsuto Tamai

Michiya Matsusaki

Takehiko Yamazaki

Yoshiki Sakai

Akifumi Matsuyama

Hiroshi Komoda

Hiroko Iseoka

Yasufumi Kaneda

Takayuki Maruyama

Kiyotoshi Sekiguchi

Masaki Mori

Hideaki Sakai

Yuichiro Doki

Manabu Shimogami

Kenji Oyama

Tadashi Sameshima

Yoshihiko Hirata

Kazuhisa Matsuda

Shigeo Masuda

Mizuyuki Ryu

Masahiro Tanemura

Toshinori Ito

Iichiro Shimomura

Satoshi Taketani

Shinji Ozawa

Fumiya Ohashi

Taro Nagai

Nanase Ishii

Shin Kawamata

Takasumi Goto

Shinya Fukui

Yoshinobu Murakami

Hirokazu Hirata

Yukiko Ochi

Takashi Kido

Fumiya Oohashi

Motoki Tatsumi

Asuka Nogami

Hirotatsu Ohkawara

Daisuke Kajita

Takaaki Samura

Junya Yokoyama

Yoshio Nakahara

Hanayuki Ohkura

Ryouhei Takeuchi

Sokichi Kamata

Yoshiki Watanabe

Hikaru Matsuda

Takayoshi Ueno

Yuzuru Kanakura

Koichi Toda

Toru Kuratani

Akira Myoui

Antti Markus Siltanen

Satoru Sakakida

Nagako Sougawa

Masaki Taira

Yukiko Imanishi

Norikazu Maeda

Go Watanabe

A method for producing a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel, the method comprising:

Method for producing fibrin sheet

It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

Transplant material for treatment of heart disease

A cell cryopreservation method including adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid.

Cell cryopreservation composition and cryopreservation method

A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.

Method for increasing the proportion of desired cells from induced pluripotent stem cells

The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.

Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure

When detachment of a cell sheet from a culture dish has started at an unintended timing, immediately detach the cell sheet from the culture dish while preventing generation of wrinkles and the like in the cell sheet. A cell culture device captures an image of cells in the culture dish, and controls a cooling mechanism and a shaking mechanism based on the image so as to shake the cells while cooling them.

Cell culture device

A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.

Myocardial cell sheet

The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of:

Method for preparing pluripotent stem cell-derived cardiomyocyte population

The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.

Drug-eluting stent graft

Disclosed is a cell mass containing an adipose-tissue-derived multipotent progenitor cell. Also disclosed is a method for producing an adipose-tissue-derived multipotent progenitor cell from an adipose tissue, which comprises the steps of: (a) removing erythrocytes from an adipose-tissue-derived cell mass to produce a preadipose-tissue-derived multipotent progenitor cell mass; and (b) removing cells other than the adipose-tissue-derived multipotent progenitor cell from the preadipose-tissue-derived multipotent progenitor cell mass to produce the desired adipose-tissue-derived multipotent progenitor cell. Further disclosed is an adipose-tissue-derived multipotent progenitor cell produced by the method.

Multipotent progenitor cell derived from adipose tissue

A laminate of a sheet-shaped cell culture is disclosed, which has excellent operability and is suitable for implantation. A method is disclosed for producing a laminate of a fibrin gel and a sheet-shaped cell culture, including a step of dripping a liquid containing fibrinogen onto an upper surface of a sheet-shaped cell culture, a step of spraying a liquid containing thrombin onto the surface, and a step of forming a fibrin gel layer on the surface by a reaction between fibrinogen and thrombin; and a laminate of a fibrin gel and a sheet-shaped cell culture produced by the method are disclosed.

Method for producing laminate of sheet-shaped cell culture and fibrin gel

A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Method for treating cardiac infarction using HMGB1 fragment

Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.

Advanced heart failure treatment material as myocardial/cardiovascular regeneration device

The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.

Three-dimensional tissue structure

A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on.

Method for obtaining pancreatic endocrine cells from adipose tissue-origin cells

Growing community of inventors

Suita, Japan

Yoshiki Sawa